CRIS Current Research Information System

VENTURI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.006
EU - Europa 2.346
AS - Asia 2.088
AF - Africa 174
SA - Sud America 159
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 7.780
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.977
SG - Singapore 654
GB - Regno Unito 637
CN - Cina 632
IT - Italia 379
SE - Svezia 341
VN - Vietnam 329
DE - Germania 303
HK - Hong Kong 198
RU - Federazione Russa 129
IN - India 128
BR - Brasile 113
NL - Olanda 107
FR - Francia 99
IE - Irlanda 82
TG - Togo 58
ZA - Sudafrica 55
EE - Estonia 51
CH - Svizzera 45
FI - Finlandia 40
UA - Ucraina 39
JO - Giordania 35
NG - Nigeria 30
BG - Bulgaria 29
KR - Corea 27
AR - Argentina 25
CI - Costa d'Avorio 22
JP - Giappone 22
IR - Iran 20
BE - Belgio 17
CA - Canada 17
PL - Polonia 12
AT - Austria 10
MX - Messico 9
EC - Ecuador 7
LB - Libano 6
SC - Seychelles 6
BD - Bangladesh 5
ES - Italia 5
GR - Grecia 5
ID - Indonesia 5
TR - Turchia 5
PK - Pakistan 4
QA - Qatar 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
CL - Cile 3
IQ - Iraq 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
VE - Venezuela 3
BO - Bolivia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
EU - Europa 2
KZ - Kazakistan 2
LT - Lituania 2
LV - Lettonia 2
MY - Malesia 2
PT - Portogallo 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
IL - Israele 1
MA - Marocco 1
MK - Macedonia 1
PE - Perù 1
RS - Serbia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.780
Salva come PNG Salva come JPEG
Città #
Southend 597
Singapore 407
Ashburn 363
Chandler 357
Fairfield 258
Hong Kong 194
Houston 158
Beijing 155
Seattle 139
Woodbridge 139
Wilmington 135
Dong Ket 117
Princeton 116
Ann Arbor 110
Cambridge 87
Dublin 82
Boardman 79
Bologna 72
Santa Clara 72
Lomé 58
New York 58
Nanjing 55
Westminster 54
Padova 51
Hefei 45
Bern 42
Medford 42
Ho Chi Minh City 38
Los Angeles 38
Amman 35
Munich 29
Sofia 29
Abeokuta 27
Redmond 27
Bremen 26
Hebei 26
Helsinki 26
Seoul 25
Hanoi 24
Jinan 24
Milan 24
Shenyang 23
Abidjan 22
Buffalo 22
Redondo Beach 22
Saint Petersburg 22
Berlin 21
Frankfurt am Main 20
San Diego 19
Jiaxing 18
Brussels 17
Falls Church 16
Redwood City 16
São Paulo 16
Nanchang 15
Changsha 14
Tokyo 14
Tianjin 13
Guangzhou 12
Nuremberg 12
Tehran 11
Turin 11
Dallas 10
Florence 10
Mountain View 10
Shanghai 10
Turku 10
Zhengzhou 10
Falkenstein 9
Norwalk 9
Rome 9
Paris 8
Dearborn 7
London 7
Ningbo 7
Phoenix 7
Atlanta 6
Bengaluru 6
Chengdu 6
Fuzhou 6
Montreal 6
Torino 6
Toronto 6
Vienna 6
Warsaw 6
Brescia 5
Curitiba 5
Johannesburg 5
Stockholm 5
Brooklyn 4
Bühl 4
Chicago 4
Denver 4
Doha 4
Düsseldorf 4
Farra d'Isonzo 4
Fremont 4
Haikou 4
Haiphong 4
Hangzhou 4
Totale 5.037
Salva come PNG Salva come JPEG
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 226
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 212
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 200
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 183
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 182
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 173
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 171
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 169
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 168
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 159
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 157
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 154
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 154
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 153
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 151
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 146
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 144
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 138
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 138
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 136
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 135
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease 135
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 133
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 132
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 130
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 129
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 128
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 128
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 128
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 127
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 127
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 127
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 125
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 124
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 123
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 123
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 121
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 121
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 118
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 118
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 117
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 115
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 114
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 113
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 109
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 108
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 108
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 106
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 105
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 104
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 102
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 101
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 101
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 100
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 82
null 76
Totale 7.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.973
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021526 0 0 0 0 0 34 18 32 84 31 44 283
2021/20221.082 98 19 58 86 123 71 11 49 56 88 195 228
2022/20231.300 153 197 49 177 107 112 34 81 207 26 85 72
2023/2024347 11 60 21 36 21 88 14 29 23 15 10 19
2024/20251.227 48 186 124 105 123 44 101 30 22 150 53 241
2025/20261.291 244 188 221 154 347 137 0 0 0 0 0 0
Totale 7.954